Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Serum cystatin C and the risk of Alzheimer disease in elderly men.

Authors: Sundelof, J  Arnlov, J  Ingelsson, E  Sundstrom, J  Basu, S  Zethelius, B  Larsson, A  Irizarry, MC  Giedraitis, V  Ronnemaa, E  Degerman-Gunnarsson, M  Hyman, BT  Basun, H  Kilander, L  Lannfelt, L 
Citation: Sundelof J, etal., Neurology. 2008 Sep 30;71(14):1072-9.
Pubmed: (View Article at PubMed) PMID:18824671
DOI: Full-text: DOI:10.1212/01.wnl.0000326894.40353.93

BACKGROUND: Multiple lines of research suggest that increased cystatin C activity in the brain protects against the development of Alzheimer disease (AD). METHODS: Serum cystatin C levels were analyzed at two examinations of the Uppsala Longitudinal Study of Adult Men, a longitudinal, community-based study of elderly men (age 70 years, n = 1,153 and age 77 years, n = 761, a subset of the age 70 examination). Cox regressions were used to examine associations between serum cystatin C and incident AD. AD cases were identified by cognitive screening and comprehensive medical chart review in all subjects. RESULTS: On follow-up (median 11.3 years), 82 subjects developed AD. At age 70 years, lower cystatin C was associated with higher risk of AD independently of age, APOE4 genotype, glomerular filtration rate, diabetes, hypertension, stroke, cholesterol, body mass index, smoking, education level, and plasma amyloid-beta protein 40 and 42 levels (hazard ratio [HR] for lowest [<1.12 micromol/L] vs highest [>1.30 micromol/L] tertile = 2.67, 95% CI 1.22-5.83, p < 0.02). The results were similar at age 77 years (43 participants developed AD during follow-up). Furthermore, a 0.1-mumol/L decrease of cystatin C between ages 70 and 77 years was associated with a 29% higher risk of incident AD (HR 1.29, 95% CI 1.03-1.63, p < 0.03). CONCLUSIONS: Low levels of serum cystatin C precede clinically manifest Alzheimer disease (AD) in elderly men free of dementia at baseline and may be a marker of future risk of AD. These findings strengthen the evidence for a role for cystatin C in the development of clinical AD.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 2314333
Created: 2009-11-11
Species: All species
Last Modified: 2009-11-11
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.